REGN - リジェネロン・ファ―マシュ―ティカルズ （Regeneron Pharmaceuticals Inc.） リジェネロン・ファ―マシュ―ティカルズREGNのチャート
REGNの企業情報
| symbol | REGN |
|---|---|
| 会社名 | Regeneron Pharmaceuticals Inc. （リジェネロン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 リジェネロン・ファーマシューティカルズ(Regeneron Pharmaceuticals Inc)は重症疾患に使われる医薬品の発見・発明・開発・生産・商品化を行うバイオ医薬品会社である。同社は眼疾患、高密度リポタンパク質（LDL）コレステロール、炎症性疾患の医薬品を商品化し、慢性関節リウマチ、喘息、アトピー性皮膚炎、疼痛、がん、感染症などの分野に開発する製品候補を有する。同社は、EYLEA（aflibercept）注射剤、Praluent（アリロクマブ）注射剤、ARCALYST（rilonacept）皮下注射剤、Kevzara（sarilumab）皮下注射剤、ZALTRAP（ziv-aflibercept）注射剤を販売する。 リジェネロン・ファ―マシュ―ティカルズは米国の大手バイオ医薬品会社。主にがん、眼病、炎症に対する治療薬の開発、製造、販売に従事。主要な製品は加齢黄斑変性症と網膜中心静脈閉塞の黄斑浮腫治療薬「EYLEA」、転移性結腸直腸がん治療薬「ZALTRAP」、抗炎症剤「ARCALYST」など。本社はニューヨーク州。 Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases. |
| 本社所在地 | 777 Old Saw Mill River Road Tarrytown NY 10591-6707 USA |
| 代表者氏名 | P. Roy Vagelos P. Roy Vagelos |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 914-347-7000 |
| 設立年月日 | 32143 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1991年 |
| 従業員数 | 6200人 |
| url | www.regeneron.com |
| nasdaq_url | https://www.nasdaq.com/symbol/regn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 2430.382 |
| 終値（lastsale） | 394.17 |
| 時価総額（marketcap） | 42592570691.16 |
| 時価総額 | 時価総額（百万ドル） 41378.5 |
| 売上高 | 売上高（百万ドル） 6202.627 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 40400.885 |
| 当期純利益 | 当期純利益（百万ドル） 1917.428 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Regeneron Pharmaceuticals Inc revenues increased 12% to $3.12B. Net income increased 62% to $1.03B. Revenues reflect Net product sales increase of 11% to $1.98B Bayer Collaboration Revenue increase of 26% to $510.8M Other revenue increase of 16% to $197.2M. Net income benefited from Payroll and Benefits decrease of 4% to $280.7M (expense). |
REGNのテクニカル分析
REGNのニュース
Biogen''s 2nd Alzheimer''s Antibody, BeiGene''s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors 2022/12/27 14:11:56 Benzinga
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB ), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI ). What Happened: This clearly suggests that the sell-off is more acute in the small-cap space. More importantly, the declines of the year came on top of sharp losses experienced by the sector in 2021. See Also: Best Biotech Socks Right Now The year was a forgettable one from the fundamental perspective too. Drug innovation dwindled, as evident from the drop in new molecular entity approvals from 50 in 2021 to 34 in 2022. The alleviation of the COVID-19 situation did not bode well for vaccine manufacturers and their stocks pulled back in line with the reduced forecast for vaccine sales. December proved to be a mixed month for FDA approvals. Mirati Therapeutics Inc. ’s (NASDAQ: MRTX ) adagrasib, a KRAS G12C inhibitor, received the nod for treating a certain type of lung cancer.
Regeneron''s Libtayo approved in Japan for cervical cancer (NASDAQ:REGN) 2022/12/23 14:01:57 Seeking Alpha
Japanese regulators have granted marketing authorization to Regeneron''s (REGN) Libtayo (cemiplimab) for advanced or recurrent cervical cancer.
Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer 2022/12/23 14:00:00 Finanz Nachrichten
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Libtayo…
Regeneron: Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published 2022/12/22 01:18:00 Finanz Nachrichten
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents …
Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference 2022/12/19 21:01:00 Regeneron Pharmaceuticals
TARRYTOWN, N.Y. , Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 . The presentation is scheduled for 9:00 a.m. Pacific Time ( 12:00 p.m.
Regeneron Director Tessier-Lavigne Files to Sell $5.1M in Stock 2022/09/30 15:55:02 Investing.com
https://www.investing.com/news/pro/regeneron-director-tessierlavigne-files-to-sell-51m-in-stock-432SI-2903099
Regeneron announces FDA approval for Dupixent to treat prurigo nodularis 2022/09/29 12:36:07 westfaironline
A regulatory filing for prurigo nodularis is under review by the European Medicines Agency. The post Regeneron announces FDA approval for Dupixent to treat prurigo nodularis appeared first on Westfair Communications .
US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis 2022/09/29 11:11:23 Pharmaceutical Business Review
This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human The post US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis appeared first on Pharmaceutical Business review .
Sanofi, Regeneron win FDA approval for Dupixent in chronic, skin condition (NASDAQ:REGN) 2022/09/29 10:51:02 Seeking Alpha
The FDA has approved Dupixent, developed by Regeneron (REGN) and Sanofi (SNY) (SNYNF) (GCVRX), for adults with prurigo nodularis, a chronic, inflammatory skin condition. The…
Regeneron: FDA Approves Dupixent For Prurigo Nodularis Treatment 2022/09/29 02:52:00 Finanz Nachrichten
PARIS (dpa-AFX) - The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, Regeneron Pharmaceuticals Inc. (REGN) and Sano…
WHO Recommends Against Roche, GSK''s COVID-19 Therapies Rendering Them Obsolete 2022/09/16 14:12:25 Benzinga
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. WHO experts said they strongly advised against using GSK plc (NYSE: GSK ) / Vir Biotechnology Inc''s (NASDAQ: VIR ) sotrovimab and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) / Roche Holdings AG''s (OTC: RHHBY ) antibody cocktail casirivimab-imdevimab. The recommendation comes as part of a suite of recommendations published in the British Medical Journal . The two therapies designed to work by binding to the … Full story available on Benzinga.com
Intellia, Regeneron tout gene editing in ATTR amyloidosis cardiomyopathy (NASDAQ:NTLA) 2022/09/16 12:08:13 Seeking Alpha
Intellia Therapeutics (NTLA) and Regeneron (REGN) announced Friday that NTLA-2001, a genome editing therapy targeted at heart-related issues in transthyretin ((ATTR)) amyloidosis, cut…
Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels 2022/09/16 11:52:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Intellia Therapeutics, Inc. (NTLA) and Regeneron Pharmaceuticals, Inc. (REGN) reported positive interim results from an ongoing phase 1 clinical trial of NTLA-2001, an inves…
WHO advises against use of GSK/Vir, Regeneron drugs for COVID, backs use of remdesivir 2022/09/16 10:32:21 Seeking Alpha
The World Health Organization in its updated guidelines recommended against the use of GSK (GSK) and Vir Biotechnologys'' (VIR) sotrovimab Regeneron Pharmaceuticals'' (REGN) antibody…
WHO ‘strongly advises against’ use of 2 COVID treatments 2022/09/15 23:36:42 Rappler
LONDON, United Kingdom – Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant’s latest offshoots have likely rendered them obsolete. The two therapies – which are designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells – were some of the first medicines developed early in the pandemic. The virus has since evolved, and mounting evidence from lab tests suggests the two therapies – sotrovimab as well as casirivimab-imdevimab – have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the US health regulator. On Thursday, September 15, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published in the British Medical Journal. GSK and partner Vir Biotechnology’s sotrovimab – which has generated billions in sales and became one of the British drugmaker’s top sellers last year – was pulled off the US market by the US Food and Drug Administration (FDA) in April.